Agios Pharmaceuticals, Inc. AGIO
Regular-session close
After hours · Nov 19, 5:15 PM ET
- YTD
- +5.66%
- 1 year
- +28.74%
5D -0.69 (-2.21%)
- Market cap
- 1.72B
- Revenue (ttm)
- 140.84M
- Profit margin
- -264.76%
- EPS (ttm)
- -6.31
- Shares out
- 59.81M
- Forward P/E
- -9.00
- YTD return
- +5.66%
- 1-year return
- +28.74%
- 50-day average
- 32.86
- 200-day average
- 31.88
- Volume
- 469.83K
- Avg volume
- 1.06M
- Open
- 29.93
- Previous close
- 29.68
- Day's range
- 28.71 – 30.35
- 52-week range
- 23.00 – 44.09
- Beta
- 0.62
- Analysts
- Buy
- Price target
- 46.11 (+60.3%)
- Earnings date
- Feb 11, 2027
Key statistics
- Enterprise value
- 1.17B
- Price / sales
- 12.21
- Price / book
- 1.76
- Revenue growth
- 330.00%
- Free cash flow
- -264.32M
- Total cash
- 630.01M
- Total debt
- 26.53M
- Return on equity
- -32.95%
- Short % of float
- 11.02%
Fundamental scorecard
7 of 25 checks passed on AGIO’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 32.00
- Target (mean)
- 46.11
- Target (high)
- 74.00
- Strong buy0
- Buy7
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate -1.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | -1.11 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.24 | -1.09 | +0.15 | +12.10% |
| Jul 30, 2026 | Jun 30, 2026 | -1.65 | -1.69 | -0.04 | -2.42% |
| Apr 29, 2026 | Mar 31, 2026 | -1.81 | -1.69 | +0.12 | +6.63% |
| Feb 12, 2026 | Dec 31, 2025 | -1.97 | -1.85 | +0.12 | +6.09% |
| Oct 30, 2025 | Sep 30, 2025 | -1.93 | -1.78 | +0.15 | +7.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Truist Securities | main | Buy | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Neutral | Neutral |
| Jul 31, 2026 | Citigroup | main | Buy | Buy |
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- agios.com
News
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals Q3 2026 Earnings Call Transcript Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Your note
Sign in to keep a note on AGIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS CATHERINE OWEN | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 10,865 |
| BACKSTROM JAY T | Director | Stock Award(Grant) | Jul 7, 2026 | 1,447 |
| BALLAL RAHUL D. | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 15,230 |
| CAPELLO JEFFREY D | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 10,865 |
| FOSTER-CHEEK KAYE I | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 12,484 |
| FOUSE JACQUALYN A. | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 154,156 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.42% | 6,229,199 | 179.15M | Sep 29, 2026 |
| Farallon Capital Management LLC | 9.93% | 5,939,400 | 170.82M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 6.50% | 3,888,907 | 111.84M | Sep 29, 2026 |
| Morgan Stanley | 5.75% | 3,436,589 | 98.84M | Sep 29, 2026 |
| State Street Corporation | 5.46% | 3,264,652 | 93.89M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.77% | 2,850,204 | 81.97M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 1,889,447 | 54.34M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.85% | 1,703,564 | 48.99M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.83% | 1,695,533 | 48.76M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 1,528,264 | 43.95M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,362,732 | 39.19M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 788,655 | 22.68M | Jun 29, 2026 |
